title: Intestinal absorption of ursodeoxycholic acid in patients with extrahepatic biliary obstruction and bile drainage.
abstract: Ursodeoxycholic acid (UDCA) dissolves cholesterol gallstones and improves liver function test results in patients with cholestatic liver diseases. Its absorption was studied in patients who had complete extrahepatic biliary obstruction caused by pancreatic carcinoma but no intestinal or liver disease. Six patients received 500 mg chenodeoxycholic acid (CDCA) or 250-2000 mg UDCA in capsules in single oral doses in random order, with an interval of 2 days between the different treatment regimens. In the control period the patients excreted into bile 382.3 +/- 108.0 mumol CDCA (mean +/- SD) and 1866.7 +/- 172.6 mumol cholic acid per 24 hours. After administration of 1273.6 mumol (500 mg) CDCA, biliary excretion of this bile acid increased to 1370.9 +/- 185.7 mumol/24 h, indicating an intestinal absorption rate of 77.6% +/- 9.8%. After oral administration of 636.8 mumol (250 mg), 1273.6 mumol (500 mg), 2547.2 mumol (1000 mg), and 5094.4 mumol (2000 mg) of UDCA, the respective absorption rates were 60.3% +/- 7.4%, 47.7% +/- 9.0%, 30.7% +/- 7.5%, and 20.8% +/- 3.9%, and whereas in the control period no UDCA was detected in the bile, the UDCA percentages measured were 14.6% +/- 8.2%, 19.6% +/- 9.1%, 23.1% +/- 11.3%, and 27.4% +/- 12.1%. The coadministration of CDCA did not enhance the absorption of UDCA. The data indicate that absorption of orally administered CDCA is almost complete, whereas UDCA absorption is incomplete. With increasing doses UDCA absorption decreases. To achieve absorption of adequate amounts of UDCA, high and/or multiple doses are needed.
authors.affiliation: Department of Gastroenterology, Robert-Bosch-Krankenhaus, Stuttgart, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Walker
authors.forename: G
authors.initials: G
authors.lastname: Rudolph
authors.forename: R
authors.initials: R
authors.lastname: Raedsch
authors.forename: A
authors.initials: A
authors.lastname: Stiehl
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D000704:Analysis of Variance; D001646:Bile / Q000378:metabolism; D001663:Bilirubin / Q000097:blood; D002635:Chenodeoxycholic Acid / Q000493:pharmacokinetics; D001651:Cholestasis, Extrahepatic / Q000378:metabolism*; D019826:Cholic Acid; D002793:Cholic Acids / Q000652:urine; D004305:Dose-Response Relationship, Drug; D004322:Drainage; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007408:Intestinal Absorption / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000378:metabolism*; D014580:Ursodeoxycholic Acid / Q000493:pharmacokinetics*
chemical_list: D002793:Cholic Acids; D004338:Drug Combinations; D002635:Chenodeoxycholic Acid; D014580:Ursodeoxycholic Acid; D000469:Alkaline Phosphatase; D019826:Cholic Acid; D001663:Bilirubin